Helen Torley

Person

Last mentioned: Feb 19, 2026

Stories mentioning Helen Torley 2

earnings Neutral

Halozyme Q4 2025: Revenue Growth Masked by Significant Non-GAAP Earnings Miss

Halozyme Therapeutics reported Q4 2025 revenue of $451 million, beating expectations on the back of strong royalty growth from its ENHANZE platform. However, a surprise Non-GAAP EPS loss of $0.24, missing estimates by over $2.00, highlights intensifying operational costs and strategic shifts in its drug delivery portfolio.

3 sources
pharma Neutral

Halozyme Q4 2025: ENHANZE Royalty Growth and Opdivo SC Launch Outlook

Halozyme Therapeutics reported robust Q4 2025 results, driven by record royalty revenue from its ENHANZE drug-delivery platform and key partnerships with Roche and Argenx. The company is positioning 2026 as a transformative year, centered on the high-stakes commercial launch of subcutaneous Opdivo in collaboration with Bristol Myers Squibb.

3 sources